<SUBMISSION>
<ACCESSION-NUMBER>0000950123-09-058958
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20091105
<ITEMS>5.02
<ITEMS>9.01
<FILING-DATE>20091106
<DATE-OF-FILING-DATE-CHANGE>20091106
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>RXI PHARMACEUTICALS CORP
<CIK>0001390478
<ASSIGNED-SIC>2834
<IRS-NUMBER>000000000
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-33958
<FILM-NUMBER>091163130
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>60 PRESCOTT  STREET
<CITY>WORCESTER
<STATE>MA
<ZIP>01605
<PHONE>508-767-3861
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>60 PRESCOTT  STREET
<CITY>WORCESTER
<STATE>MA
<ZIP>01605
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>b77967e8vk.htm
<DESCRIPTION>RXI PHARMACEUTICALS, INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>








<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>


<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(D) OF THE<BR>
THE SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>
Date of report (Date of earliest event reported): November&nbsp;5, 2009</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">RXI PHARMACEUTICALS CORPORATION
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></B>
</DIV>

<DIV align="center" style="font-size: 10pt">
(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Delaware
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">001-33958
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">20-8099512</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of <BR>
of incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission<BR>
File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
60 Prescott Street, Worcester, MA 01605<BR>

<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>(Address of Principal Executive Offices) (Zip Code)<BR>

Registrant&#146;s telephone number, including area code: (508)&nbsp;767-3861</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I>
General Instruction A.2. below):
</DIV>
<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD valign="top"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD valign="top"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD valign="top"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD valign="top"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</TD>
</TR>
</TABLE>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;5.02</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.</B></TD>
</TR>
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;As part of a plan succession in leadership, Tod Woolf, Ph.D., resigned as President, Chief
Executive Officer and a member of the Board of Directors (the &#147;Board&#148;) of RXi Pharmaceuticals
Corporation, effective November&nbsp;5, 2009. Dr.&nbsp;Woolf&#146;s decision to resign was not a result of any
disagreement with the Company or its management. Dr.&nbsp;Woolf will remain with the Company as a
member of its scientific advisory board.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(c)&nbsp;On November&nbsp;5, 2009, the Board appointed Noah D. Beerman as its President and Chief Executive
Officer, effective immediately. Mr.&nbsp;Beerman, age 47, has over 25&nbsp;years of experience in the
biopharmaceutical industry. From 1997 until April&nbsp;2009, Mr.&nbsp;Beerman held a variety of leadership
positions, most recently serving as Executive Vice President and Chief Business Officer at Indevus
Pharmaceuticals, Inc., which was acquired by Endo Pharmaceuticals in March&nbsp;2009. Prior to joining
Indevus, Mr.&nbsp;Beerman was responsible for health care as vice president at Technology Management and
Funding (&#147;TMF&#148;), a venture firm where he developed and executed business and commercialization
strategies for TMF&#146;s biotechnology portfolio. Earlier in his career, he served in a variety of
business and scientific capacities at Creative BioMolecules, Sandoz AG, and Repligen. Mr.&nbsp;Beerman
holds an M.B.A. from Northeastern University&#146;s High Technology Program and a B.S. in molecular
genetics from the University of Rochester. Mr.&nbsp;Beerman does not have a family relationship with
any existing member of the Board or any executive officer of the Company.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of Mr.&nbsp;Beerman&#146;s employment agreement (the &#147;Agreement&#148;), the Company is
obligated to appoint him to the Board promptly following the effective date of the Agreement. Mr.
Beerman is also entitled to a sign-on bonus of $25,000, options to purchase 350,000 shares of
common stock of the Company which will vest quarterly in equal installments over four years, an
annual base salary of $375,000, and Mr.&nbsp;Beerman may be eligible for an annual bonus determined by
the Company in its sole discretion. The Agreement expires on December&nbsp;31, 2011, but may be
terminated by the Company or Mr.&nbsp;Beerman at any time. If the Company terminates Mr.&nbsp;Beerman&#146;s
employment without cause (as defined in the Agreement), or if Mr.&nbsp;Beerman terminates his employment
for good reason (as defined in the Agreement), Mr.&nbsp;Beerman will be entitled to (a)&nbsp;salary, option
vesting and continued participation in the Company-sponsored group benefit plan during the
Severance Period (as defined in the Agreement) and (b)&nbsp;a bonus incentive for targets achieved in
full prior to the date of termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A copy of the press release announcing the events described above is being filed as Exhibit
99.1 to this report and is incorporated herein by reference.
</DIV>
<!-- link2 "Item&nbsp;9.01 Financial Statements and Exhibits." -->

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;9.01</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Financial Statements and Exhibits.</B></TD>
</TR>
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;Exhibits</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">99.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD valign="top" style="font-size: 10pt">&nbsp;</TD>
    <TD valign="top" style="font-size: 10pt"><DIV style="margin-left:0px; text-indent:-0px">Press Release issued by RXi Pharmaceuticals Corporation on November&nbsp;6, 2009</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 " Signature" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Signature</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">RXI PHARMACEUTICALS CORPORATION<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: November 6, 2009&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Konstantinos Andrikopoulos
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Konstantinos Andrikopoulos&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Vice President, Legal Counsel&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>b77967exv99w1.htm
<DESCRIPTION>EX-99.1 PRESS RELEASE ISSUED BY RXI PHARMACEUTICALS CORPORATION ON NOVEMBER 6, 2009
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="b77967b7796701.gif" alt="(RXI LOGO)">
</DIV>


<DIV align="center" style="font-size: 14pt; margin-top: 18pt"><B>RXi Pharmaceuticals Appoints Noah D. Beerman as CEO</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 6pt"><B>Business Veteran Brings to RXi a Successful Track Record of Building a Pipeline<BR>
of Biopharmaceutical Products</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Worcester, MA, November&nbsp;06, 2009 &#151; </B>RXi Pharmaceuticals Corporation (Nasdaq: RXII), a
biopharmaceutical company pursuing the development and commercialization of proprietary
therapeutics based on RNA interference (RNAi), today announced that Noah D. Beerman has joined the
company as its new President and Chief Executive Officer. The appointment of Mr.&nbsp;Beerman as CEO is
part of a planned succession in leadership as the company looks to advance from the research stage
to product development and execution of therapeutic collaborations and partnerships. He succeeds
RXi&#146;s co-founder, Tod Woolf, Ph.D., who will continue as a member of RXi&#146;s Scientific Advisory
Board (SAB).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Beerman (47)&nbsp;joins RXi with over 25&nbsp;years of experience in the biopharmaceutical industry and
most recently served as Executive Vice President, Chief Business Officer for Indevus
Pharmaceuticals, Inc., which was acquired by Endo Pharmaceuticals in March&nbsp;2009 for $370&nbsp;million
plus future milestone payments. At Indevus, Mr.&nbsp;Beerman was responsible for the development and
implementation of the company&#146;s corporate development strategy to ensure near- and long-term growth
and success. Noah was also responsible for overseeing Indevus&#146; acquisition of Valera
Pharmaceuticals in 2007 and for managing the integration activities with Endo as part of this
transaction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Prior to joining Indevus in 1997, Mr.&nbsp;Beerman was Vice President responsible for health care at
Technology Management and Funding (TMF), a venture firm where he developed and executed business
and commercialization strategies for TMF&#146;s biotechnology portfolio. Earlier in his career, he
served in a variety of business and scientific capacities at Creative BioMolecules, Sandoz AG, and
Repligen. Mr.&nbsp;Beerman holds an M.B.A. from Northeastern University&#146;s High Technology Program and a
B.S. in molecular genetics from the University of Rochester.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;Noah brings to RXi an extensive biotechnology business background and broad scientific expertise.
We are delighted to welcome Noah to the team and believe that his experience will help transform
RXi from a research stage company into a development stage company. We are highly encouraged by
the pre-clinical data generated by RXi and are optimistic that this will lead to accelerating our
product development as well as our partnering activities. Given Noah&#146;s successful track record in
these areas, RXi should be well positioned to capitalize on these opportunities,&#148; commented Sanford
Hillsberg, RXi&#146;s Chairman of the Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We would like to thank Dr.&nbsp;Woolf, who has guided the strategic vision of RXi since early 2007,
taking the company public in 2008 and bringing RXi from a concept to a leading RNAi therapeutics
company. Under his leadership, RXi has achieved a number of important technological innovations,
including the creation of RXi&#146;s self-delivering rxRNA (sd-rxRNA&#153;) compounds that have recently
demonstrated positive results in animal models. The board would like to acknowledge Dr.&nbsp;Woolf for
his service and is delighted that he will remain with RXi as an active member of our SAB,&#148;
continued Mr.&nbsp;Hillsberg.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Beerman added, &#147;I am excited to join RXi and lead its next phase of growth. My experience in
building clinical pipelines will help guide the company as it looks to advance products using its
breakthrough technology and advanced therapeutic platform. I look forward to working with the team
to define RXi&#146;s clinical programs and in realizing the full potential of this unique and exciting
technology.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About RXi Pharmaceuticals Corporation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and
potential commercialization of proprietary therapeutics based on RNA interference (RNAi) for the
treatment of human diseases. RXi has a comprehensive therapeutic platform that includes both RNAi
compounds and potential delivery methods. RXi uses its own version of RNAi compounds &#151; rxRNA&#153; &#151;
that provide an advanced alternative to conventional small interfering RNAs (siRNAs) and may define
the next generation of RNAi technology. rxRNA&#153; compounds are designed specifically for therapeutic
use and contain many of the properties needed to move RNAi based drugs into the clinic. RXi
Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based
therapeutics market with its accomplished scientific advisors, including Dr.&nbsp;Craig Mello, recipient
of the 2006 Nobel Prize for his co-discovery of RNAi; a management team that is experienced in
developing RNAi products; and a strong early intellectual property position in RNAi chemistry and
delivery. <U>www.rxipharma.com</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forward-Looking Statements</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about
future expectations, plan and future development of RXi Pharmaceutical Corporation&#146;s products and
technologies. These forward-looking statements about future expectations, plans and prospects of
the development of RXi Pharmaceutical Corporation&#146;s products and technologies involve significant
risks, uncertainties and assumptions, including the risk that the development of our RNAi-based
therapeutics may be delayed or may not proceed as planned and we may not be able to complete
development of any RNAi-based product, the risk that the FDA approval process may be delayed for
any drugs that we develop, risks related to development and commercialization of products by our
competitors, risks related to our ability to control the timing and terms of collaborations with
third parties, risks relating to our need to raise additional capital to carry out our future
contemplated activities and the possibility that other companies or organizations may assert patent
rights that prevent us from developing our products. Actual results may differ materially from
those RXi Pharmaceuticals Corporation contemplated by these forward-looking statements. RXi
Pharmaceuticals Corporation does not undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur after the date of this release.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>CONTACT:</B><BR>
RXi Pharmaceuticals<BR>
Donna Falcetti<BR>
508-929-3615<BR>
ir@rxipharma.com

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Investors<BR>
S. A. Noonan Communications<BR>
Susan Noonan<BR>
212-966-3650<BR>
susan@sanoonan.com

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Media<BR>
Rx Communications Group<BR>
Eric Goldman<BR>
917-322-2563<BR>
egoldman@rxir.com

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>b77967b7796701.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 b77967b7796701.gif
M1TE&.#EA10!1`/<``'IZ=)U=HOKZ^I5.F8U`DM2ZUMW(WXDYC:&AG/'Q[\S+
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MGX`JA9M9H-75TY%(EG@>?OCR^+F+O'H@?^#,X>?GYN75YN74Y6)B6G!P:8^/
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MGHY"D_#G\?[^_GD>?E-32R'Y!```````+`````!%`%$```C_`*_H&TBPH,&#
M"!,J7,A0W[M]#6Y(G$BQHL6+%M6-V+BQ0(>/($.*'/FQ@`0/,KS,N\*RI<N7
M,&.^-$*KG\U8@6;HW,FSIT^=12:A++$+BM&C2),J78H4QI`C-FVB>7&JE-6K
M6+-J?4!JJ"E_8,.*'4NV+`@06OS!Z+*$5=1M.4K]FTNWKMV[7+V6W<LW+(A+
MF$"$]20@*@H=<N\J5IQ71HFO?2./!?'$"I2P<7Q$70<J\>+/<QL_EDP:K!9%
M702#W24H*A$`GD$O%@VY=.0Z&6#`"`O#150!,V++QMO5<6W;?`?D&7O&@=M^
MHZ0('UZ7-O+(+,R-U;)LF*Q^P*=3_P]=?/1ULUUJ[",[9,WWU^+'6S]/%D2F
M#D_('HA@DW-\ZO/1)Q8,6<1@!5F9G!!+/XWD<\IXC)5WG(#^0.&)`:&0904D
M"SHBQH,0VA6@/R"8LH\R*`YQP"]G]07"#NU<0E8OTMA$1PBRE?+"(#P*-R((
M0PCCRY!K",-`"D"DM1<(%@@BXUB[>&$3#L.%\\`<<V`#(ETC^I,%*E'=1$PE
M?9TS@B"8S%AC+`C4(MLIJMB4P);DZ276ES9!P@`3P+`RC16JD16*`0;\HB$D
MX$GA)FAPRIF*B!*.A6<_*NRRQ"W],$)`H&-904(8'R#HARP;;#+<*0\88XP"
MCU87Z9U@4O^JA`TVN8+';F5]`$8$<9#U1#>SS%'-J2^$8"QQ=H8UJ0IGT-J/
M*ZW@2M8'830Q`%D$,#(+E?_-=0J=D"8+UK+-UAKM7G!(XPP2TH(U0!.L4-`M
M755=%:YQDL;*K+/0MBO6)3'(,DEJ?N4Q2@*@4'>*#I)(L@>X79++[[E[-2`+
MK]+"H$(_<U"C<)S])-`JEZ\JJV^YSU)<'Q6L\**'DB1:T(\AXS4:\LAUX@NK
M3?N:ZZ]?#N#"2A@TJ/9+#`+L,:^W((M\KWDF\XQROTL^TH0LHW#1!0R4=0.-
M#C4WC?,_$9\\\<]@V>>'3?P,H)L[3$P5MJ-/3RBQSTN>8X1;K##_\('&H\BS
MZ*EBUYVOU,Z*H')9*4!@$R(J=-'`(BN`^YG-3KLJKI?ZSFJ3IFB'1<,)-OEY
MB#T*A&#Y8IB/7;9->F!"2#^LQ`!'Z*8)P8HLK"R1!Q&<6#7WS8;OW,\;-V#`
MB@\!@(`[B7@<(0L$*5A`>8BM%Q^U3;(T<<.UG.[5A1FL@/%(-VB(,<CJBF6O
MN<[;VV1'!&X,01H,AT10`1("4$`.`B\87N9(MKE)V:("R6`%*]31B_#5YQR=
MD($@4#`&!7Q#'`)T7<G&%2M`^,,,L@#&$0CP/+!`H0M5P``:-M&(6-`A!^RK
MB_L("#\.(LXFBBNA/[30!0N,@@)DT`5X_]+P,;J]#VHVI-34%K<7&!#`!Y3#
M053*T8=YS3!G2.3<#5-6PK/L`!>I*P(R;,(+!/PCAF<LW!'M9C:\]04&F8`$
M+=(`CF@$XCE_^!"CU$C#+-Z-BY&!0>,F<(U2G"(?Y;`),BC1K2N2;8-:5.+9
M(H.)&\BB#</Z1RDH0(1^Q&(!`;P<'['(QBU2C2\@P$,R9,$&ST1#`;>(Q6%B
MZ,C72=*-2WH'*Y(F0W&L`SH/$Z41^UC*6P*2+U:8QBP:L0(9A@`-;F$#+4?Y
MR`*V\9A[T4<3^H$%'-6E%`^P!C>]V3YJVK)GV-R./U@V,\7DH`W]^$(?A$F\
M-1[.F*>LSP?P0?\[>=VE%$7@Q3J20,\!DO*>^UI0/L<"@W?UXP))F,XIDC`!
M7J2CH!JTIM0XL*!@,-$O$G"+/!=#C3;$0A48U5X2F;4#FS#A$6B#`29&\)U[
MD/,N;`"&&5EG3DB2BP6/"\!ER`*#`PAC%OU8P&=*(0EG%"&E]O1+*UP1BUCH
M`0;SR$4L6&$"!ZI%'\.812S*,#B[E"()ZW@J3X=Y4+_4P0%(0,(AE/!6)/!A
M'$TT`=^"MYA2].$+:E5,*5;`#&90`%DU%!`,EE"Z!\2G%-7X`Q%#1$P*A<4;
M4@(/;#[S`BQ(@K*5M:P_?M6?0G)6`0``;5LMVPI?V.0;FXCA"W#03-7_=HD^
MBA@%4C=0V\6\H`PW#=%MSU.)FO3C,$NM!AG&!J'A(D=CS[E>7\6@`^;*!Y+7
M@0(,N!`5V"[U!:&T+7:?"P(J;*8SJ@70>)%37M<0-+W#$<T'8$'?^MKWOOB%
MQ2]VX1N;T.(!Q@JP@`=,X`(3F!)=&8`3UO"*!COXP1".\"O6L(8F(.+"$(C'
M*C;,X0Y[^,,@]C`[".$!3"CAQ"A.L8I7S.(6N_C%,(:!!W*1BU'8^,8XSK&.
M=\SC'OO8QS4.DY"'3.0B&_G(2$ZRDI?,Y"8[^<E0CK*4ITSE(8M`!$RX!1.8
M0`\F-($8QZ#=%D1P#%Q,`5Y5-C(K1&`'(B-"_P1AP@0<K%"!'2C##UG8@0,J
M<8MA5*$7<,B#',S!A#0/^02*P,<=$F'<,*D#"$*T20_\H(<L:.`)EG@".CI@
MR6%$0@4&J(,^#E$!%P2C`2:P@`\L8`M"6,`"[Q#$.PK@!"'(00/!<($$PN`$
M&^S@!`5@0`0L4($/5,`";]"`!&J`@1H`8A(%4$(3A*"&:=3!%@%H7"=`T`E=
M6,(2_?"T`VQ1!T74H1,?<$$<.$`#%]1A'URH@R7BH(P4#`$)=^B$*%2@#`<\
MPA++<$`5YM$,!AS`!!_@0"%,0``6M``)F7#!.6J@A`HH`QXMP,0`,L&R"L#`
M!JSX=KCO8(5#<&`'`^&`Q!,*<`,^P$((/8@!&)X0`P^PX`?[P$<B/K&/`:C@
M"#<HQ","L`]W%#P.-SB``0;@B2>`P0#<($1NB@$#,\!!!5'HP0G4,``>$$`4
M+?"!R#VM@EC(H@(I?X($#E"#.,!<`V"@00SF<7,"!$`1%1C"`$P0@1K@`0DE
ML`7!&8!TI3/=Z:A^P@W.40PE",,(`<B$UBM0""ZT(`8'<,'8/VUVM$/B&2R@
M@02L8(,>P%WN-O]!"P80`&T,@0^%:,8`,J")#,RC'D-(P0$ZD`DU9$,/+0!^
0$.+`A=XH00*/D$,=`@(`.S\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
